Kyeong-Man Hong1, Hyun-Kyoung Kim1, Seong-Yeol Park1, Shiv Poojan1, Mi-Kyung Kim1, Joohon Sung2, Betty P Tsao3, Jennifer M Grossman3, Ornella J Rullo4, Jennifer M P Woo4, Deborah K McCurdy4, Lisa G Rider5, Frederick W Miller5, Yeong-Wook Song6,7. 1. Research Institute, National Cancer Center, Goyang. 2. Department of Epidemiology, School of Public Health, Seoul National University, Seoul, Korea. 3. Department of Medicine-Rheumatology. 4. Division of Pediatric Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA. 5. Department of Health and Human Services, Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA. 6. Department of Internal Medicine. 7. Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Center, College of Medicine, Seoul National University, Seoul, Korea.
Abstract
Objective: The importance of hypomethylation in SLE is well recognized; however, the significance of hypermethylation has not been well characterized. We screened hypermethylated marks in SLE and investigated their possible implications. Methods: DNA methylation marks were screened in SLE whole-blood DNA by microarray, and two marks ( CD3Z and VHL hypermethylations) were confirmed by a methylation single-base extension method in two independent ethnic cohorts consisting of 207 SLE patients and 151 controls. The correlation with clinical manifestations and the genetic influence on those epigenetic marks were analysed. Results: Two epigenetic marks, CD3Z and VHL hypermethylation, were significantly correlated with SLE: CD3Z hypermethylation (odds ratio = 7.76; P = 1.71 × 10 -13 ) and VHL hypermethylation (odds ratio = 3.77; P = 3.20 × 10 -8 ), and the increased CD3Z methylation was correlated with downregulation of the CD3ζ-chain in SLE T cells. In addition, less genetic influence on CD3Z methylation relative to VHL methylation was found in analyses of longitudinal and twin samples. Furthermore, a higher CD3Z methylation level was significantly correlated with a higher SLE disease activity index and more severe clinical manifestations, such as proteinuria, haemolytic anaemia and thrombocytopenia, whereas VHL hypermethylation was not. Conclusion: CD3Z hypermethylation is an SLE risk factor that can be modified by environmental factors and is associated with more severe SLE clinical manifestations, which are related to deranged T cell function by downregulating the CD3ζ-chain.
Objective: The importance of hypomethylation in SLE is well recognized; however, the significance of hypermethylation has not been well characterized. We screened hypermethylated marks in SLE and investigated their possible implications. Methods: DNA methylation marks were screened in SLE whole-blood DNA by microarray, and two marks ( CD3Z and VHL hypermethylations) were confirmed by a methylation single-base extension method in two independent ethnic cohorts consisting of 207 SLEpatients and 151 controls. The correlation with clinical manifestations and the genetic influence on those epigenetic marks were analysed. Results: Two epigenetic marks, CD3Z and VHL hypermethylation, were significantly correlated with SLE: CD3Z hypermethylation (odds ratio = 7.76; P = 1.71 × 10 -13 ) and VHL hypermethylation (odds ratio = 3.77; P = 3.20 × 10 -8 ), and the increased CD3Z methylation was correlated with downregulation of the CD3ζ-chain in SLE T cells. In addition, less genetic influence on CD3Z methylation relative to VHL methylation was found in analyses of longitudinal and twin samples. Furthermore, a higher CD3Z methylation level was significantly correlated with a higher SLE disease activity index and more severe clinical manifestations, such as proteinuria, haemolytic anaemia and thrombocytopenia, whereas VHL hypermethylation was not. Conclusion:CD3Z hypermethylation is an SLE risk factor that can be modified by environmental factors and is associated with more severe SLE clinical manifestations, which are related to deranged T cell function by downregulating the CD3ζ-chain.
Authors: Thorsten Cramer; Yuji Yamanishi; Björn E Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S Firestein; Hans Peter Gerber; Napoleone Ferrara; Randall S Johnson Journal: Cell Date: 2003-03-07 Impact factor: 41.582
Authors: Patrick Coit; Matlock Jeffries; Nezam Altorok; Mikhail G Dozmorov; Kristi A Koelsch; Jonathan D Wren; Joan T Merrill; W Joseph McCune; Amr H Sawalha Journal: J Autoimmun Date: 2013-04-24 Impact factor: 7.094
Authors: Rudolf P Talens; Kaare Christensen; Hein Putter; Gonneke Willemsen; Lene Christiansen; Dennis Kremer; H Eka D Suchiman; P Eline Slagboom; Dorret I Boomsma; Bastiaan T Heijmans Journal: Aging Cell Date: 2012-06-04 Impact factor: 9.304
Authors: Hao Li; Maria G Tsokos; Sean Bickerton; Amir Sharabi; Yi Li; Vaishali R Moulton; Philip Kong; Tarek M Fahmy; George C Tsokos Journal: JCI Insight Date: 2018-08-23